24-APR-2024 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 Y 0 Screening 1420 1219 78 78 59 21 3 08/13/2019 311 118
            1219 78 78 59 21 3      
 
    2 Y 1 Lenalidomide   558 43 31 23 9 3 08/13/2019    
        2 Lenalidomide + Daratumumab   553 45 36 31 11 2      
            1111 88 67 54 20 5      
 
    3 Y 3 Stop vs Continue Treatment   179 94 37 17 8 2 08/13/2019    
            179 94 37 17 8 2      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 62 1 1 1 1 1 0 01/05/2022 66 24
        2 I+R+Venetoclax   1 0 0 0 0 0      
            2 1 1 1 1 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 7 7 6 3 2 0 10/12/2023 173 61
        2 DRD-R   7 7 7 3 1 0      
        3 DRD-DR   5 5 5 3 0 0      
            19 19 18 9 3 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   46 22 9 2 0 0 05/27/2021 185 82
            46 22 9 2 0 0      
 
    1 E Total Registrations   35 17 8 3 1 0 05/27/2021    
            35 17 8 3 1 0      
 
    2 E Total Registrations   17 10 5 2 1 0 05/27/2021    
            17 10 5 2 1 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   61 15 8 4 1 0 01/08/2020 226 96
            61 15 8 4 1 0      
 
    1 E Total Registrations   26 4 2 0 0 0 01/08/2020    
            26 4 2 0 0 0      
 

24-APR-2024 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Induction 01-Dec-23 57 19
  2 Randomization 01-Dec-23 57 19
  3 Maintenance 01-Dec-23 57 19